zh-twzhen
zh-twzhen

News-Outstanding Corporate Governance Evaluation Results for the Microbio Group Microbio and Oneness Rank among Top 5% in the Corporate Governance Evaluation for Four Consecutive years; Diamond Biofund Enters Top 5% on Its First Evaluation

2023

Date

Title

2023-06-29

Oneness was notified today that Bonvadis, the wound care topical cream has submitted medical device registration to South African Health Products Regulatory Authority.

>
2023-06-28

SNS812, a broad-spectrum siRNA co-developed by Oneness and Microbio (Shanghai) to treat SARS-CoV-2 infection, was greenlighted by TFDA to proceed with a Ph2 study

>
2023-06-28

Oneness Biotech Co., Ltd. receives a Vietnamese patent titled “TOPICAL FORMULATION FOR PROMOTING WOUND HEALING” on Fespixon cream (Research code: ON101).

>
2023-06-21

Oneness announces the information about the investor’s conference of 2023 Q2.

>
2023-06-21

The Phase 3 MRCT data and the Taiwan real-world cases of the DFU new drug, Fespixon have been accepted for an oral presentation at 2023 ADA’s 83rd Scientific Sessions.

>
2023-06-09

Oneness submitted an IND to TFDA for a phase II clinical trial on the broad-spectrum anti-SARS-CoV-2 siRNA (SNS812) co-developed with Microbio (Shanghai)

>
2023-06-06

The National Agency of Drug and Food Control(Badan Pengawas Obat dan Makanan; BPOM) has accepted the NDA application of the diabetic foot ulcer new drug, Fespixon

>
2023-06-01

Oneness Biotech Co., Ltd. receives the United States patent on the producing recombinant glycoproteins with modified glycosylation.

>
2023-05-31

Oneness submitted an IND to US FDA for a phase II clinical trial on the broad-spectrum anti-SARS-CoV-2 siRNA (SNS812) co-developed with Microbio (Shanghai)

>
2023-05-30

Announced The Board of Directors’ resolution of 2023 that the related matters of ex-rights and ex-dividend.

>
2023-05-23

Oneness announces on behalf of Cotton Field Organic Farm Inc., a major subsidiary, for shareholders’ meeting important resolutions of the 2023

>
2023-05-11

The Company’s 2023Q1 consolidated financial statements have been approved by the Board of Directors

>
2023-05-08

Oneness Attends the 9th International Symposium on Diabetic Foot 2023 (ISDF2023)

>
2023-05-02

The Phase 3 MRCT post-hoc analysis and the post-market hard-to-heal cases of the DFU new drug, Fespixon have been accepted for an oral presentation at EWMA 2023.

>
2023-05-02

Oneness Biotech Co., Ltd. receives a Singaporean patent titled “TOPICAL FORMULATION FOR PROMOTING WOUND HEALING” on Fespixon cream (Research code: ON101).

>